VentriPoint Diagnostics Ltd (TSXV: VPT, OTCQB: VPTDF) is an Ontario-based equipment company engaged in developing and distributing heart disease diagnostic equipment.
It is medical device manufacturer that provides cardiac diagnostic tools services worldwide. VentriPoint delivers high-quality and smart tools to understand the heart structure and functioning without relying on MRI. As a result, it claims to help patients improve their clinical experience.
The company says that VMS+ is designed to create a three-dimensional model of the heart from a two-dimensional echocardiogram without sonography. It offers fast, accurate and reproducible measurements.
The Canadian company offers KBR Technology that uses images of the heart, creates a 3D model and helps in calculating volumes and ejection fractions for all chambers.
As an artificial intelligence leader in echocardiography, the firm says that the KBR Technology helps develop accurate volumetric cardiac measurements comparable to MRI.
In March 2021, Ventripoint Diagnostics reportedly initiated training for Chinese cardiologists in Heart Analysis System through its joint venture partnership agreement with Yutian Medical Shanghai Inc.
In April 2021, the company collaborated with GE Healthcare’s Edison Developer Program. This collaboration allows the company to extend its existing customer base of cardiologists reportedly. GE Healthcare claims to aid clinicians in taking informed decision using data analytics, applications, intelligent devices, and related services.
In addition, it offers pharmaceutical diagnostics and digital solutions services. To extend and evaluate the cardiac measurement capabilities of the VMS+, the company claims to receive funding of up to $120,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) in May 2021. With this funding, the firm aims to improve the healthcare systems and add clinical value to VMS+ Products. It establishes advanced cardiac measurement and offers a complete echo cardiac analysis package consisting of 2D measurements and 3D measurements delivered by the VMS+ using 2D ultrasound.
The Canadian firm says that the product enhancement helps to prevent cardiac disease and provide a diagnosis of cardiac disease globally.
In January 2021, the company agreed to collaborate with a veterinary hospital located in North Carolina State University. Under the arrangement, the medical tech company agreed will test and identify the use of VMS+ in the echocardiography of canines.
Ventripoint aims to broaden its portfolio and increase its innovative technology to strengthen cardiac care for animals and offers a solution for veterinarians.